Immunovant Inc

Immunovant Inc

IMVT

Get informed when a big investor buys or sells

+ Follow
Market Cap$7.63B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Immunovant IncImmunovant Inc-13.1--73%--
$4.94

Current Fair Value

85.5% downside

Overvalued by 85.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$7.63 Billion
Enterprise Value$6.83 Billion
Dividend Yield$- (-)
Earnings per Share$-2.77
Beta0.81
Outstanding Shares205,545,373

Return

Return on Equity-73.19%ROE
Return on Assets-63.13%
Return on Invested Capital-60.45%

Valuation & Multiples

P/E Ratio-13.1P/E Ratio
PEG-48.46PEG
Price to Sales-Price to Sales
Price to Book Ratio11.33Price to Book Ratio
Enterprise Value to Revenue962.47
Enterprise Value to EBIT-15.36
Enterprise Value to Net Income-13
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 9, 2026
EPS Estimate
$-0.73
Average shareholder expectation
Revenue Estimate
$7.09 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1536▲ 4.90%
Total Calls1,801,100▼ 28.30%
Total Puts276,600▲ 5.25%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %54.04%▼ 6.59%
Total Invested$4.28B▲ 55.73%
Investors Holding240▲ 14.00%

ESG Score

No data

About Immunovant Inc